$MYMD News

Last published 2y ago

2y agoMYMD TNFATNF Pharmaceuticals (Formerly MyMD Pharmaceuticals) Begins Trading Under New Nasdaq Stock Symbol "TNFA" Effective Before Market Open TodayBusiness WireNew name and stock symbol represents therapeutic focus on inhibiting TNF-alpha to regulate the immuno-metabolic system TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) (formerly MyMD Pharmaceuticals, Inc.) (the "Company"), a
2y agoMYMDMyMD Pharmaceuticals Announces Corporate Rebranding to New Name TNF Pharmaceuticals, Inc.Business WireNew name represents therapeutic focus on inhibiting TNF-alpha to regulate the immuno-metabolic system Company plans mid-stage clinical trials of TNF-alpha inhibitor drug MYMD-1® following statistically
2y agoMYMDMyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief Medical OfficerBusiness WireDr. Glass brings a 35-year career in life sciences with multiple drug approvals including Accolate ®, Avandia ® and Coreg® Dr. Glass brings broad expertise in regulatory strategies: 5 NDAs and MAAs, 7
2y agoMYMD PMCBMyMD Pharmaceuticals Secures Strategic InvestmentsBusiness WireUp to $42 Million in Two-Part Funding from New Strategic Investor and Existing Shareholders with Committed Closing of an Aggregate of $14 Million Up Front MyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD) ("MyMD" or "the
2y agoMYMD PMCBPharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory DiseaseBusiness WireSecond external investment in life sciences solidifies previously announced strategy to utilize significant cash position to create additional stockholder value PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or
2y agoMYMDMyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued ListingBusiness WireMyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD) ("MyMD" or "the Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory
2y agoMYMDMyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq ListingBusiness WireCommon Stock Will Begin Trading on Split-Adjusted Basis on February 15, 2024 MyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD) ("MyMD" or "the Company"), a clinical stage biopharmaceutical company committed to developing
2y agoMYMDMyMD Pharmaceuticals Releases Positive Clinical Trial Results For Sarcopenia Treatment DrugACCESS NewswireBALTIMORE, MD / ACCESSWIRE / December 29, 2023 / A condition that commonly affects elderly populations, sarcopenia results in the gradual loss of strength and physical function and has become an important healthcare
2y agoMYMDMyMD Pharmaceuticals Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid ArthritisBusiness WireCompany targets first quarter 2024 for trial initiation Potential to be first orally-administered TNF-α inhibitor treatment for RA MyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD) ("MyMD" or "the Company"), a clinical
3y agoMYMDMyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD™, Reduced Acute Inflammatory PainBusiness Wire- Supera-CBD eased heat-related pain due to inflammation quickly and provided long-lasting pain relief lasting up to five hours - Results suggest Supera-CBD may target specific pain pathways, lessening the potential
3y agoMYMDMyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-α Market Disrupter, at BioFuture 2023Business Wire- Company to share new positive, statistically significant results across Cohort 4 (1050mg) from Phase 2 study of MYMD-1 in sarcopenia, an age-related frailty disorder - MyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD)
3y agoMYMDFDA Accepts MyMD Pharmaceuticals' Investigational New Drug Application (IND) for Phase 2 Study of oral TNF-α inhibitor MYMD-1® in Rheumatoid Arthritis (RA)Business Wire- Next-generation and first oral TNF-α inhibitor, which completed Phase 2 study for age-related condition sarcopenia, represents a potentially groundbreaking advance in the treatment of RA and disruption of a $41
3y agoMYMDMyMD Pharmaceuticals to Hold Conference Call Today to Discuss Phase 2 Trial ResultsBusiness WireMyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD) ("MyMD" or the "Company"), a clinical stage pharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions,
3y agoMYMDMyMD Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral TNF-α Inhibitor MYMD-1® in Sarcopenia/Age-Related FrailtyBusiness Wire- MYMD-1 significantly reduced serum levels of chronic inflammatory markers and met all primary pharmacokinetic and secondary safety and tolerability endpoints across multiple doses over 28 days of treatment - MYMD-1
3y agoMYMDMyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy LifespanBusiness Wire- Currently, there are no FDA-approved treatments for sarcopenia/frailty - - MyMD is only 3 patients away from dosing its final patient in its first Phase 2 clinical trial of lead drug candidate MYMD-1® - MyMD
3y agoMYMDMyMD Pharmaceuticals® and Charles River Present Positive Data for Next Generation, Oral TNF-α Inhibitor MYMD-1® in Rheumatoid ArthritisBusiness WirePreclinical results showed MYMD-1® significantly reduced histopathological changes and the severity of standard arthritis clinical trial measures compared to placebo; demonstrate future potential to disrupt the
3y agoMYMDMyMD Joins LOT Network in Effort to Protect Company and Shareholders from Patent TrollsBusiness WireMyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD) ("MyMD" or "the Company"), a clinical stage biopharmaceutical company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and
3y agoMYMDMyMD Announces U.S. Drug Enforcement Administration (DEA) Determines Supera-CBD™ is not a Controlled Substance or Listed ChemicalBusiness Wire-- DEA scientific review concludes Supera-CBD will not be classified as a regulated chemical or require scheduling during development -- MyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD) ("MyMD" or "the Company"), a
3y agoMYMDMyMD Pharmaceuticals® Announces Upcoming Presentation of Preclinical Rheumatoid Arthritis Data for Oral TNF-α Inhibitor MYMD-1® at the Society of Toxicology 2023 Annual MeetingBusiness Wire-- Study results comparing the anti-inflammatory effects of MYMD-1® to Enbrel (etanercept) accepted for poster presentation -- MyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD) ("MyMD" or "the Company"), a clinical
3y agoMYMDMyMD Announces $15 Million Offering with Existing InvestorsBusiness WireMyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD) ("MyMD" or "the Company"), a clinical stage biopharmaceutical company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and
3y agoMYMDMyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022Business Wire- Preclinical and early clinical studies of MYMD-1®, an oral, small-molecule, selective TNF-α inhibitor, suggest future potential to disrupt the Rheumatoid Arthritis market - MyMD Pharmaceuticals, Inc.®
3y agoMYMDMyMD Pharmaceuticals® Announces Upcoming Presentation of Late-Breaking Data for MYMD-1® at the 2022 British Society for Immunology (BSI) CongressBusiness Wire- Preclinical and early clinical studies of MYMD-1®, an oral, small-molecule, selective TNF-α inhibitor accepted for presentation - MyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD) ("MyMD" or "the Company"), a
3y agoMYMDMyMD Pharmaceuticals Announces Publication of Phase 1 Data for oral TNF-alpha Inhibitor MYMD-1® in Peer-Reviewed Journal Drug ResearchBusiness WireMYMD-1 demonstrated favorable safety and tolerability profile across multiple doses, with no clinically relevant adverse events, supporting advancement of the compound for Sarcopenia and Rheumatoid Arthritis MyMD
4y agoMYMDMyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy LifespanBusiness WireEfficacy data anticipated in Q4 of 2022 MyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD) ("MyMD" or "the Company"), a clinical stage biopharmaceutical company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and
4y agoMYMDMyMD Pharmaceuticals Receives Grant From European Patent Office for Supera-CBD™ CompoundBusiness WireAllowed Claims Cover Supera-CBD™ as a New Molecular Entity and Pharmaceutical Formulations Containing the Compound MyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD) ("MyMD"), a clinical stage pharmaceutical company committed to developing novel therapies
4y agoMYMDData Showing MyMD Pharmaceuticals' MYMD-1® May Extend Life and Improve Health Published in the Journal of Gerontology: Biological SciencesBusiness WireStudy of oral TNF-α inhibitor MYMD-1 demonstrates significant improvements in lifespan and maintenance of health characteristics compared to rapamycin MyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD) ("MyMD" or "the Company"), a clinical stage pharmaceuti
4y agoMYMDMyMD Pharmaceuticals® Advances Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy LifespanBusiness WireSarcopenia trial shows no evidence of toxicity or safety issues and patients were enrolled in the next higher dose of MYMD-1 MyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD) ("MyMD" or "the Company"), a clinical stage pharmaceutical company committed to de
4y agoMYMDMyMD Pharmaceuticals to Collaborate with Bascom Palmer Eye Institute to Study MYMD-1 in Ophthalmic ConditionsBusiness WireBascom Palmer Eye Institute ranked the #1 eye hospital in the United States for 20 years in a row by U.S. News & World Report MyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD) ("MyMD" or "the Company"), a clinical stage pharmaceutical company committed to d
4y agoMYMDMyMD Pharmaceuticals Advances Phase 2 Multi-Center Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy LifespanBusiness WireEfficacy data expected in second half of 2022 MyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD) ("MyMD" or "the Company"), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced further advancement in its fully-fund
4y agoMYMDMyMD Pharmaceuticals' Lead Compound MYMD-1 Demonstrates Superior Anti-inflammatory Effects over Top-Selling Therapies in a Pivotal Preclinical Model of Rheumatoid ArthritisBusiness WireMyMD seeks to disrupt the $31 billion global market for rheumatoid arthritis (RA) drug therapies with MYMD-1, which could potentially prove safer, more effective and better tolerated than current options Submission of Investigational New Drug (IND) a
4y agoMYMDMyMD Pharmaceuticals Accelerates Pace of New Patient Dosing in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy LifespanBusiness Wire28-day dosing regimen completed by several patients to date Efficacy data from fully funded Phase 2 trial is expected in first half of 2022 MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) ("MyMD" or "the Company"), a clinical stage pharmaceutical company
4y agoMYMDMyMD Pharmaceuticals Announces Live Appearance on Cheddar News Network Today March 24Business WireMyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) ("MyMD" or "the Company"), a clinical-stage pharmaceutical company committed to extending healthy lifespan, announced today that Dr. Adam Kaplin, Chief Scientific Officer, will appear as a featured guest on the C
4y agoMYMDMyMD Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy LifespanBusiness WireEfficacy data from fully funded Phase 2 trial is expected in first half of 2022 MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) ("MyMD" or "the Company"), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that
4y agoMYMDMyMD Pharmaceuticals Announces Positive Clinical Data in Advance of Upcoming Phase 2 Trial of MYMD-1 for Extending Healthy LifespanBusiness WirePhase 1 dose-ranging study results meet primary endpoints Drug demonstrates statistically significant efficacy in reducing levels of the root cause of aging, TNF-α, in the blood Data from fully funded Phase 2 trial anticipated in first half o
4y agoMYMDMyMD Pharmaceuticals Announces Issuance of New U.S. Patent Covering MYMD-1 in a Method of Treating SarcopeniaBusiness WireExpands intellectual property portfolio for lead drug candidate MYMD-1 to 3 U.S. patents related to aging and extending healthy lifespan, 16 patents in total MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) ("MyMD" or "the Company"), a clinical stage pharmac
4y agoMYMD ORMPMyMD Pharmaceuticals Investment Company Oravax Medical Signs Cooperation and Purchase Agreement for Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccine to be Commercialized in Southeast AsiaBusiness WireIn addition to pre-purchase order, parties have agreed to negotiate potential follow-on orders that could be significant MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) ("MyMD" or "the Company"), a clinical-stage pharmaceutical company committed to extendin
4y agoMYMDMyMD Pharmaceuticals to Participate in Two Investor Conferences During December 2021Business WireMyMD to highlight its development pipeline for two novel therapeutics: immune regulator MYMD-1 and synthetic cannabidiol derivative Supera-CBD MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) ("MyMD" or "the Company"), a clinical stage pharmaceutical company
4y agoMYMDMyMD Pharmaceuticals Announces Issuance of U.S. Patent Covering Lead Drug Candidate MYMD-1 in a Method of Extending LifespanBusiness WireExpands intellectual property portfolio for lead drug candidate MYMD-1 to 12 U.S. patents MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) ("MyMD" or "the Company"), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying
4y agoBMV:LABB MYMD ORMPMyMD Pharmaceuticals Investment Company Oravax Medical and Genomma Lab Announce Joint Venture to Develop and Commercialize Oral COVID-19 Vaccine in Mexico and Drive Business Development in Latin AmericaBusiness WireMillions of people in the region could benefit from the COVID-19 vaccine candidate- faster, easier, without the cold chain: The Oravax Oral Vaccine The new partnership builds on the respective strengths of Oravax Medical and Genomma Lab to create com
4y agoMYMDMyMD Pharmaceuticals Receives FDA IND Clearance to Begin Phase 2 Trial of MYMD-1 for Extending Healthy LifespanBusiness WireBelieved to be the only IND application ever cleared by the FDA for a Phase 2 trial of a patented drug for delaying aging Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022 MyMD Pharmaceutic
5y agoMYMDMyMD Pharmaceuticals President Chris Chapman, M.D. Named Medical Honoree of the Year by the Arthritis FoundationBusiness WireMyMD's lead drug candidate, MYMD-1, is being developed to target aging and related diseases along with autoimmune diseases including rheumatoid arthritis MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) ("MyMD" or "the Company"), a clinical stage pharmaceuti
5y agoMYMDMyMD Pharmaceuticals to Discuss its Novel Therapies for Aging and Related Diseases at the Dawson James Securities 6th Annual Small Cap Growth Conference on October 21Business WireMyMD is pursuing high value opportunities in a massive healthcare market with no known competing FDA-approved drugs for treating aging disorders and extending healthy lifespan MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) ("MyMD" or "the Company"), a clin
5y agoMYMD CRTX HYFM AZEK+1Cramer's lightning round: Azek Company is a great stock hereCNBC"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.
5y agoMYMDMyMD Pharmaceuticals to Detail its Two Upcoming Phase 2 Trials at the Benzinga Rising Stars: Catalytic Small Cap Growth Conference on October 7Business WireMyMD to launch two simultaneous Phase 2 trials during the current quarter to study MYMD-1's function in extending healthy lifespan and treating COVID-19-associated depression MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) ("MyMD" or "the Company"), a clin
5y agoMYMDMyMD Pharmaceuticals Announces New Data Demonstrating 8,000 Times Higher Potency of Novel Synthetic Supera-CBD over Plant-Derived CBDBusiness WireData indicates potential of drug candidate to deliver an extremely potent therapeutic benefit at a very low non-toxic dose New data will be presented at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston MyMD Pharmac
5y agoMYMDMyMD Pharmaceuticals Announces Fourth Quarter 2021 Initiation of Phase 2 Clinical Trial of MYMD-1 for Extending Healthy LifespanBusiness WireKey objective of the trial is to reduce levels of the protein that causes inflammation and activates aging, TNF-α, in the blood MYMD-1 is designed to become the first and only FDA-approved therapeutic solution for delaying aging and prolonging life
5y agoMYMDMyMD Pharmaceuticals to Present its Novel Therapeutic Platforms for Extending Healthy Lifespan at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15Business WireMyMD to highlight its development pipeline for MYMD-1, an immunometabolic regulator, and Supera-CBD, a synthetic cannabidiol derivative MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) ("MyMD" or "the Company"), a clinical stage pharmaceutical company commit
5y agoMYMDMyMD Pharmaceuticals Announces Issuance of U.S. Patent for Use of Lead Candidate MYMD-1 for Treating Fibrosis and AsthmaBusiness WirePatent protects methods of administering MYMD-1 for treating disorders associated with chronic inflammation, with a focus on fibrosis and asthma MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) ("MyMD" or "the Company"), a clinical stage pharmaceutical compa
5y agoMYMDMyMD Pharmaceuticals Announces Issuance of U.S. Patent for Synthetic Cannabinoid Compounds for Treating Neuroinflammatory and Neurodegenerative DiseasesBusiness WirePatent protects Supera-CBD, shown to be 7-8X more effective than plant-derived CBD in reducing enzymes that play a key role in pain, inflammation, and neurodegeneration MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) ("MyMD" or "the Company"), a clinical st
5y agoMYMD ORMPMyMD Pharmaceuticals Subsidiary Oravax Medical Preparing to Commence Clinical Trials for Oral COVID-19 VaccineBusiness WireOravax's virus-like particle (VLP) vaccine being tested against COVID-19 variants including Delta Oral COVID-19 vaccine being developed as both a standalone vaccine and a booster for people previously vaccinated MYMD is evaluating options for